![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » LABOPHARM FILES FOR ONCE-DAILY TRAMADOL IN CANADA
LABOPHARM FILES FOR ONCE-DAILY TRAMADOL IN CANADA
Labopharm announced that its new drug submission for its extended-release formulation of tramadol has been accepted for review by the Therapeutic Products Directorate of Health Canada. The NDS is subject to a targeted 300-day review period.
"It is our intention to commercialize our once-daily tramadol product in key markets globally, and Canada represents a significant opportunity," James Howard-Tripp, the company's president and CEO, said.
Labopharm's application for its once-daily formulation of tramadol includes comprehensive data generated during the course of a global clinical development program similar to that included in the company's new drug application to the FDA.
Tramadol, an opiate analgesic, is currently available in Canada only in an immediate-release formulation of the product that combines tramadol with acetaminophen.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct